Breastfeeding, Antiretroviral, and Nutrition Study
NCT00164736 is a phase 3 interventional trial sponsored by Centers for Disease Control and Prevention. As of 21 Nov 2026, it is completed. It studies Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir in HIV Infections. The registry lists an enrollment of 2,369 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2004 and a primary completion date of 31 Jan 2010. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00164736 |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Centers for Disease Control and Prevention |
| Enrollment | 2,369 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | HIV Infections |
| Drugs | Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir |
| Start | 31 Mar 2004 |
| Primary completion | 31 Jan 2010 |
| Study completion | 31 Jan 2010 |
| Last update posted | 23 Apr 2010 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Charles van der Horst, MD
University of North Carolina, Chapel Hill
Study Chair - Peter Kazembe, MB ChB
Kamuzu Central Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Kamuzu Central Hospital, Bottom Hospital
Lilongwe
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00164736
Each answer restates registry values shown on this page.
What is NCT00164736?
NCT00164736 is a phase 3 interventional trial sponsored by Centers for Disease Control and Prevention. It studies Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir in HIV Infections.
Who leads NCT00164736?
The registry names Charles van der Horst, MD (study chair, University of North Carolina, Chapel Hill), Denise J Jamieson, MD, MPH (principal investigator, CDC, Atlanta, GA) and Peter Kazembe, MB ChB (principal investigator, Kamuzu Central Hospital) as overall officials.
Where does NCT00164736 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: Malawi.
Which drugs does NCT00164736 study?
The registered drug and biological interventions are Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir.
When did NCT00164736 end?
The registry lists a primary completion date of 31 Jan 2010 and a study completion date of 31 Jan 2010. The sponsor last updated the record on 23 Apr 2010.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.